Daily Newsletter

26 March 2024

Daily Newsletter

26 March 2024

Apogee Therapeutics begins dosing in allergic disease drug trial

The trial will assess APG808's safety, tolerability and pharmacokinetics in healthy subjects.

Vishnu Priyan March 26 2024

US-based biotechnology company Apogee Therapeutics has begun dosing healthy subjects in its Phase I clinical trial of APG808, a potential treatment for various Type 2 allergic diseases.

The trial will assess the therapy’s potential to treat moderate-to-severe chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune diseases.

A subcutaneous extended half-life monoclonal antibody (mAb), APG808 acts on IL-4Rα, a clinically validated target across eight Type 2 allergic diseases.

The placebo-controlled, single-ascending dose trial aims to enrol nearly 32 healthy adult subjects across four cohorts to assess APG808's safety, tolerability and pharmacokinetics.

Interim data from the study is anticipated in the second half of this year.

Following the Phase I trial and subject to positive results and the submission of an investigational new drug (IND) application or its international equivalent, Apogee plans to begin a Phase Ib trial of the therapy in asthma patients.

The data readout from this subsequent trial is expected in the first half of next year.

In addition, a placebo-controlled, randomised Phase II trial of APG808 in patients with moderate-to-severe COPD is expected to launch next year.

Apogee Therapeutics chief medical officer Carl Dambkowski said: “By targeting known biologic drivers of disease and utilising advanced antibody engineering such as improved half-life, Apogee aims to overcome limitations of existing therapies for inflammatory and immune diseases.

“We demonstrated the potential benefits of optimising antibody properties with APG777 and now hope to do the same with APG808, which, in head-to-head preclinical studies, demonstrated similar potency to current therapies but with a significantly longer half-life.

“Importantly, this points to potentially less frequent dosing for patients with COPD, which could significantly improve quality of life.”

Last August, Apogee dosed the first participants ahead of schedule in a Phase I study of APG777 to potentially treat moderate-to-severe atopic dermatitis and other inflammatory diseases.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close